All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


hiv & aids news selected from other sources

  • Pharmaceutical industry
    GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?
    FiercePharma | 11 July 2019

    GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

  • Harm reduction
    UK: Take home naloxone is not reaching those who most need it
    The BMJ | 11 July 2019

    Naloxone is key is to addressing the current opioid crisis, but poor systemic distribution means it isn’t saving the lives it should, says Zoe Carre

  • HIV and criminal law
    "Tiger Mandingo,” Who Got 30 Years For Not Telling Sex Partners He Had HIV, Is Free 25 Years Early
    BuzzFeed | 11 July 2019

    Michael Johnson, who was sentenced to an unprecedented 30.5 years for failing to disclose his HIV status to his sexual partners, was released today, 25 years early, after an appeals court condemned his original trial as “fundamentally unfair.” In a racially and sexually charged trial, he had received a longer sentence than many murderers do.

  • Long-acting HIV treatment
    Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics
    Lyndra Therapeutics press release | 10 July 2019

    Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

  • Epidemiology
    Louisiana HIV Rates Are the Lowest in a Decade
    POZ | 10 July 2019

    Doctors attribute the drop to increased testing and U=U.

  • PrEP programmes and uptake
    PrEP Trials Offer Insight for Reaching at-Risk Women in Sub-Saharan Africa
    Contagion Live | 10 July 2019

    Reaching individuals at high risk of acquiring HIV infection continues to pose a challenge to uptake of HIV pre-exposure prophylaxis (PrEP). A new study looked at PrEP clinical trials in sub-Saharan Africa, examining recruitment strategies to reach women at high risk of contracting HIV.

  • PrEP programmes and uptake
    Same-day PrEP initiation a favorable option for patients at risk for HIV
    Healio | 10 July 2019

    Same-day initiation of pre-exposure prophylaxis, or PrEP, for HIV prevention was found to be safe, feasible and well-received among patients at a walk-in STD clinic, according to a recently published study. During the study, which was conducted at a clinic in Denver, a high proportion of the participants were linked to ongoing PrEP care, researchers reported.

  • Vaccinations and immunisations
    HPV vaccine for boys 'will prevent thousands of cancers'
    BBC News | 09 July 2019

    Health officials say the HPV vaccine for 12 to 13-year-old boys, starting after the summer, will prevent 29,000 cancers in UK men in the next 40 years.

  • TB treatment
    Will a new TB treatment be available soon?
    Devex | 08 July 2019

    Experts advising the U.S. Food and Drug Administration on marketed and investigational drugs for infectious diseases and disorders were divided on whether the regulatory agency should approve a new drug as part of a proposed combination therapy for highly resistant tuberculosis. The majority of the independent experts — 14 out of 18 — advising the regulatory agency voted favorably last month. But the remaining four found insufficient evidence on efficacy and safety of the TB Alliance’s oral anti-TB drug pretomanid when used in combination with bedaquiline and linezolid, or BPaL.

  • PrEP policies and guidelines
    NHS England recommends uncapped PrEP trial access
    National Health Executive | 08 July 2019

    NHS England have announced five steps towards better access to the HIV prevention drug PrEP, including recommending removing the capped number of places on the ongoing IMPACT Trial. This follows a meeting yesterday between Simon Stevens, chief executive of NHS England, NAT (National AIDS Trust), Terrence Higgins Trust, and PrEPster.

Conference news

Coming soon: news from IAS 2019. Sign up for our IAS conference bulletins.


Read the latest edition of the Sexual Health & HIV Policy EUROBulletin.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.


Watch our AIDS 2018 aidsmapLIVE panel discussion on YouTube.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.